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Single studies attempting to associate ANP gene T2238C (rs5065) polymorphism with hypertension have so far reported
inconclusive results. We therefore aimed to evaluate this association via a meta-analysis. Data on 7 studies with a total of 4068
subjects were available and analyzed using the random-eﬀects model with assessment of heterogeneity and publication bias.
Overall comparison of 2238C with 2238T yielded a 23% reduced, albeit nonsigniﬁcant, risk for hypertension (95% CI: 0.38–
1.59; P = .485), while accompanying signiﬁcant heterogeneity (I2 = 88.3%) and publication bias (P = .051). Subgroup analysis
by study design demonstrated opposite associations between population-based (OR = 0.33; 95% CI: 0.13–0.80; P = .015) and
hospital-based studies (OR = 1.15; 95% CI: 0.79–1.68; P = .454). Further meta-regression analysis exclusively indicated the
signiﬁcant inﬂuence of study design (P = .042) on heterogeneity. Taken together, these ﬁndings support the notion that carriers
of 2238C allele were at moderate decreased risk of developing hypertension, whereas study design was identiﬁed as a potentially
signiﬁcant source of between-study heterogeneity.
1.Introduction
Hypertension is a complex syndrome inﬂuenced by multiple
genetic and environmental factors [1]. In view of some
individualsbeingmore susceptibletohypertension thanoth-
ers, it is essential to explain this interindividual diﬀerential
susceptibility [2]. Although great hope was expressed in
genome-wide association studies to unlock the genetic basis
of hypertension, the results from such research, however,
have told us little [3]. Given the limited power of single
studies, one practicable strategy is to perform large meta-
analyses to reliably evaluate the predetermined candidates in
genetic association studies.
The gene encoding atrial natriuretic peptide (ANP,
chromosome 1p36.21) is a logical candidate for involvement
in the underlying cause of hypertension. The candidacy
of ANP gene is well deﬁned. Knockout mice deﬁcient in
one copy of ANP gene was associated with salt-sensitive
hypertension [4]. In contrast, overexpression of ANP gene
via gene therapy in hypertensive mice had lowered systolic
blood pressure [5]. These ﬁndings therefore encourage
the search for human genetic polymorphisms that aﬀect
the ANP functionality. A large panel of ANP gene poly-
morphisms have been identiﬁed; in particular, an exonic
polymorphism T2238C (rs5065) ranks high in association
with hypertension; however, the results in some individually
underpowered studies are often irreproducible [6, 7]. To
derivea more precise estimation, we therefore meta-analyzed
the association of ANP gene T2238C polymorphism with
occurrence of hypertension from both English and Chinese
literature, while addressing between-study heterogeneityand
publication bias.2 International Journal of Hypertension
2.Methods
2.1. Search Strategy for Identiﬁcation of Studies. We searched
PubMed and EMBASE, as well as China Biological Medicine
(http://sinomed.imicams.ac.cn/index.jsp) and Wanfang
(http://www.wanfangdata.com.cn) databases for articles
published before 10 February 2011 using the Boolean
combinations of keywords (atrial natriuretic peptide OR
natriuretic peptide precursor A OR ANP or NPPA) AND
(hypertension OR blood pressure) AND (polymorphism
OR allele OR genotype OR variant OR variation). Search
results were limited to human populations and articles
written in both English and Chinese languages. The full text
of the retrieved articles was scrutinized to decide whether
information on the topic of interest was included. Reference
lists of these retrieved articles and systematic reviews were
also checked to determine whether citations of articles were
not initially identiﬁed. For these articles involving more than
one geographic or ethnic heterogeneous groups, each group
was treated separately.
2.2. Inclusion/Exclusion Criteria. Articles were included in
this meta-analysis if they examined the hypothesis that ANP
gene T2238C polymorphism was associated with hyper-
tension, if they followed a case-control or cross-sectional
study design, and if they provided suﬃcient information on
T2238C genotype counts between hypertensive patients and
controls for determining an estimate of odds ratio (OR) and
its corresponding 95% conﬁdence interval (CI).
Hypertension was deﬁned as systolic blood pressure
equal to or above 140mmHg or diastolic blood pressure
equal to or above 90mmHg or previous treatment with
antihypertensive drugs. Studies evaluating secondary hyper-
tension or other types of monogenic hypertension were
excluded. Where there were multiple articles from the same
study population, the most complete and recent results were
extracted.
2.3. Extracted Information. The following characteristics
were extracted independently and entered into separate
databases by Wenquan Niu and Yue Qi (who is an assistant
researcher in Beijing Institute of Heart, Lung & Blood Vessel
Diseases, Anzhen Hospital) from each qualiﬁed study: ﬁrst
author’s last name, publication date, population ethnicity,
study design, diagnostic criteria, baseline characteristics of
the study population (such as age, gender, and body mass
index), and the T2238C genotype counts in patients and
controls. For consistency, quantitative variables expressed
as mean ± standard error (SE) were converted to mean ±
standard deviation (SD). Any encountered discrepancies
were adjudicated by a discussion, and a consensus was
reached.
2.4. Statistical Analysis. The random-eﬀects model using the
DerSimonian & Laird method was implemented to bring the
individual eﬀect-size estimates together, and the estimate of
heterogeneity was taken from the Mantel-Haenszel model
[13]. Unadjusted OR and 95% CI were used to compare
genetic contrasts between patients and controls.
Between-study heterogeneity was assessed by the incon-
sistency index I2 statistic (ranging from 0 to 100%), which
wasdocumentedforthepercentageoftheobservedbetween-
study variability due to heterogeneity rather than chance,
with higher values suggesting the existence of heterogeneity
[14, 15]. In the case of between-study heterogeneity, we
examined the study characteristics that can stratify the stud-
ies into subgroups with homogeneous eﬀects. In addition, to
estimate the extent to which one or more covariates explain
heterogeneity, meta-regression, as an extension to random-
eﬀects meta-analysis, was employed.
Cumulative meta-analysis was conducted to identify the
inﬂuence of the ﬁrst published study on the subsequent
publications, and the evolution of the combined estimates
over time according to the ascending date of publication.
To identify potentially inﬂuential studies, sensitivity analysis
was undertaken by removing an individual study each time
to check whether any of these estimates can bias the overall
estimate.
The funnel plots and Egger regression asymmetry test
were used to assess publication bias. Egger’s test can detect
funnel plot asymmetry by determining whether the intercept
deviates signiﬁcantly from zero in a regression of the
standardized eﬀect estimates against their precision.
Probability less than 0.05 was judged signiﬁcant with
the exception of the I2 statistic and Egger’s test, where
a signiﬁcance level of less than 0.1 was chosen. Data
management and statistical analyses were performed using
STATA version 11.0 for Windows.
3.Results
3.1.Search Results. Based onoursearch strategy,theprimary
screening produced 25 potentially relevant articles, of which
7 met the inclusion criteria with an attempt to evaluate
the association of ANP gene T2238C polymorphism with
t h eo c c u r r e n c eo fh y p e r t e n s i o n[ 6–12]. A total of 2041
hypertensive patients and 2027 controls were analyzed. Of
these 7 articles, three [6–8] were published in English and
four in Chinese language [9–12]. Five out of 7 articles were
conducted in Asians (four in Chinese [9–12]a n do n ei n
Japanese [8]). The detailed selection process is presented in
Figure 1.
3.2. Study Characteristics. The baseline characteristics of
qualiﬁed studies are presented in Table 1. Overall 2238C
allele frequency was 4.19% in patients and 8.14% in controls
with the highest frequency noted in an African-American
population (41.67% and 38.64%) [6]a n dt h el o w e s tf r e -
quency in a Chinese Han population (0.92% and 0.82%)
[10]. Genotyping for T2238C polymorphism across all stud-
ies,excepttwousingthegenechiptechnology[9,12]andone
using TaqMan assay [10], was conducted using polymerase
chain reaction-restriction fragment length polymorphism
(PCR-RFLP) followed by enzyme ScaI digestion.
3.3. Overall Analysis. Considering the low frequency of
2238CC genotype, we only assessed the association of 2238C
allele (relative to 2238T allele) with hypertension risk in thisInternational Journal of Hypertension 3
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Figure 1: Flow diagram of search strategy and study selection.
meta-analysis. Overall speaking, comparison of allele 2238C
with 2238T generated a 23% reduced, albeit nonsigniﬁcant,
risk for hypertension (95% CI: 0.38–1.59; P = .485)
(Figure2).Meanwhile,therewasstrongevidenceofbetween-
study heterogeneity (I2 = 88.3%, P<. 0005) and high
possibility of publication bias as reﬂected by the suggestive
asymmetry of funnel plot (Figure 3) and the Egger’s test
(P = .051).
3.4. Cumulative and Inﬂuential Analyses. In the cumulative
meta-analysis, therewasnoevidencesuggestingtheﬁrst pub-
lished study that reported a potentially signiﬁcant result and
then trigged the subsequent replication (data not shown).
However, the inﬂuential analysis revealed that there was
one study in a Kazakh Chinese population [11] inﬂuencing
the overall results signiﬁcantly (Figure 2). When this most
inﬂuential study was removed, the overall estimate was
strongly attenuated with OR approaching the unity (OR =
0.97; 95% CI: 0.62–1.51; P = .897). Likewise, between-
study heterogeneity was remarkably reduced (I2 = 51.2%,
P = .069), and there was a low probability of publication
bias (P = .479) (Figure 3).
3.5. Subgroup Analysis. Considering the signiﬁcance of
heterogeneity, we considered as a better choice to try
investigating its sources by conducting subgroup analysis in
characteristic-homogeneous groups. To evaluatethe possible
eﬀect of study design on the variability of overall estimates,
studies were divided into population-based and hospital-
based studies, and importantly the magnitude of association
in population-based studies was strikingly reinforced with
the 2238C allele conferring a signiﬁcant protective eﬀect on
hypertension (OR = 0.33; 95% CI: 0.13–0.80; P = .015),
whereas this eﬀect was reversed in hospital-based studies
with no attainable signiﬁcance (OR = 1.15; 95% CI: 0.79–
1.68; P = .454) (Figure 4(a)).
Further subgroup analysis by ethnicity suggested het-
erogeneous associations of T2238C polymorphism with
hypertension, by showing a suggestive risk eﬀect of 2238C
allele in Blacks (OR = 1.13; P = .66), a signiﬁcant
protective eﬀect in Whites (OR = 0.53; P = .019), and a
moderate protective eﬀect in Asians (OR = 0.79; P = .663)
(Figure 4(b)).
Because sample size of study is also a major factor aﬀect-
ing the reliability, we therefore used an additional strategy to
estimate the eﬀect by grouping only those large association
studies with an arbitrary cutoﬀ of 500 individuals. Two
out of seven studies had sample sizes greater than 500 and
conferred a 53% reduced risk for 2238C allele relative to
2238T allele (95% CI: 0.09–2.45; P = .374), accompanying
high between-study heterogeneity (I2 = 94.7%, P<. 0005)
(Figure 4(c)).
3.6. Meta-Regression Analysis. To further account for be-
tween-study heterogeneity within a multivariable frame-
work, we performed meta-regression by incorporating var-
ious study-level covariates including averaged levels of
age, male percent, and body mass index (BMI) between
patients and controls, as well as study design and ethnicity
altogether, and we interestingly and exclusively observed
that study design was a signiﬁcant source of between-study
heterogeneity (P = .042).4 International Journal of Hypertension
Table 1: The baseline characteristics of all qualiﬁed studies in this meta-analysis.
Author, ref and year Country
(Ethnicity) Design Status Age, year Gender,
M( % ) BMI, kg/m2 SBP,
mmHg
DBP,
mmHg
T2238C
TT TC CC
Rahmutula et al. [8]
2001
Japan
(Japanese) H-B Cases 50 (8) 65.67 24.7 (3.7) 170
(20)
105
(12) 222 11 0
Controls 49 (10) 69.95 23 (3.1) 115
(13)
70
(10) 200 13 0
Nannipier et al. [7]
2001
Europe
(White) P-B Cases 56 (11) 47.93 25.9 (2.8) 141
(15)
86
(10) 95 26 0
Controls 41 (10) 47.62 24.4 (3.2) 122
(14)
78
(8) 67 37 1
Rutledge et al. [6]
1995
US
(Black) H-B Cases 44.7 (15.2) 56.70 —∗ — — 17 36 7
Controls 44.8 (14.7) 65.90 — — — 19 16 9
Hu et al. [9]
2010
China
(Han
Chinese)
H-B Cases 57.71 (9.97) 48 23.79 (2.99) 171.47
(13.01)
100.74
(8.34) 97 3 0
Controls 55.05 (10.64) 43.30 24.24 (4.50) 115.66
(10.99)
73.49
(8.15) 93 4 0
Tian and Cheng [10]
2010
China
(Han
Chinese)
H-B Cases 59.89 (9.81) 72.00 24.33 (3.69) 170.95
(23.86)
105.67
(14.35) 960 14 2
Controls 59.68 (9.78) 70.00 23.31 (3.21) 115.59
(20.85)
70.20
(11.00) 962 12 2
Li et al. [11]
2005
China
(Kazakh
Chinese)
P-B Cases 46.80 (7.82) 40.89 26.27 (4.84) 168.53
(24.72)
104.51
(15.02) 273 35 5
Controls 45.75 (8.63) 45.37 25.16 (5.63) 117.39
(11.36)
73.95
(8.58) 205 187 16
Wang and Mao [12]
2009
China
(Han
Chinese)
H-B Cases 68.61 (12.76) 57.14 — — — 220 18 0
Controls 68.45 (13.19) 59.27 — — — 179 5 0
Ref:referencenumber;P-B:population-baseddesign;H-B:hospital-baseddesign;M(%):male(percent);BMI: bodymassindex;SBP:systolicblood pressure;
DBP: diastolic blood pressure. ∗Information not available. Data are expressed as mean (SD) unless otherwise indicated.
4.Discussion
This study, including 4068 subjects, to our knowledge, is the
ﬁrst meta-analysis examining the relationship between ANP
gene T2238C polymorphism and hypertension. Although
some statistical biases could not be eliminated, our results
suggested that carriers of 2238C allele were at moderate
decreased risk of developing hypertension, whereas study
design was identiﬁed as a potentially signiﬁcant source of
between-study heterogeneity by both subgroup and meta-
regression analyses, indicating the robustness of our results.
Genetic heterogeneity is an inevitable problem in any
disease identiﬁcation strategy [16]. As shown in this study,
we speculated that ANP gene T2238C polymorphism might
have diverse roles in diﬀerent ethnic populations. On one
hand, striking diﬀerences were noted in terms of mutant
2238C allele frequency between African-Americans and
Asians, with the former almost tenfold higher than the latter,
suggesting that diﬀerent genetic backgrounds may cause
this discrepancy, or diﬀerent populations may have diﬀerent
linkage disequilibrium patterns. A polymorphism may be in
closelinkagewithanothernearbycausalvariantinoneethnic
population but not in another [17]. The ANP gene T2238C
polymorphism may be in close linkage with diﬀerent nearby
causal variants in diﬀerent populations. On the other hand,
in our subgroup analysis, T2238C polymorphism showed
signiﬁcant heterogeneous associations with hypertension
across diﬀerent ethnic groups, with 2238C allele in African-
Americans being completely at odds with that in Whites
and Asians, suggesting that this polymorphism might have
a multifunctional role in the pathogenesis of hypertension
or interact with other genetic and environmental factors.
However, considering the relative small sample sizes in each
group, we suggest that conﬁrmation in large, well-designed
studies is critical.
Besidesthedisturbing inﬂuenceofethnicity in thismeta-
analysis, it should still be treated with caution because
of diﬀerent study designs. Interestingly, we observed that
magnitude of association was reversed in population-based
studies relative to in hospital-based studies although no
signiﬁcance wasidentiﬁedforthelatter.Regardingthispoint,
we agree that control for population stratiﬁcation remainsInternational Journal of Hypertension 5
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Figure 2: Overall risk estimate of ANP gene 2238C versus 2238T allele for hypertension (a) and the presentation of its inﬂuential analysis
(b).
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Figure 3: Funnel plots for studies investigating the eﬀect of ANP gene T2238C polymorphism on the risk of hypertension in overall allelic
model (a) and after excluding the most inﬂuential study (b). Vertical axis represents the log of OR; horizontal axis represents the SE of
log(OR). Funnel plots are drawn with 95% conﬁdence limits. OR, odds ratio; SE, standard error. The graphic symbols represent the data in
the plot sized proportional to the inverse variance.6 International Journal of Hypertension
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Figure 4: Subgroup analysis of ANP gene T2238C polymorphism with hypertension by study design (a), ethnicity (b), and sample size
(cutoﬀ: 500 individuals) (c) in the allelic model.International Journal of Hypertension 7
an important consideration in hospital-based studies [18],
because in this meta-analysis, most studies have recruited
subjects from only one hospital, and thus there might be a
narrow socioeconomic proﬁleforbothpatientsand controls.
Moreover, in hospital-based studies, poor comparability
between cases and controls might exert a confounding eﬀect
on the true association in light of a regional specialty for the
disease under study and the diﬀerential hospitalization rates
between cases and controls [19]. In contrast, subjects drawn
from community or a ﬁxed group might be representative of
the true population, leading us to believe that results from
population-based studies might hold the water. Considering
the wider conﬁdence intervals of estimates and small sample
sizes in population-based studies, more studies are required
to quantify this eﬀect size reliably.
Despite the clear strengths of our study including rela-
tively large sample sizes and robustness of statistical analyses,
interpretation of our current study, however, should be
viewed in light of several technical limitations. Because only
published studies were retrieved in this meta-analysis and
the “grey” literature (articles in languages other than English
and Chinese) was not included, publication bias might
be possible, even though our funnel plots and statistical
tests did not show it. In addition, most studies in this
meta-analysis have recruited subjects aged ≥50 years, for
whom environmental factors are likely to contribute more
prominentlythanthegeneticcomponenttothedevelopment
ofhypertension[20],suggestingthatlargeassociationstudies
inayoungerpopulationofhypertensive subjectsareofadded
interest. Moreover, the single-locus-based nature of meta-
analysis precluded the possibility of gene-gene and gene-
environment interactions, as well as haplotype-based eﬀects,
suggesting that additional studies assessing these aspects will
be necessary. Furthermore, we only centered on ANP gene
T2238C polymorphism and did not cover other candidate
genes or polymorphisms. It seems likely that the T2238C
polymorphism individually makes a moderate contribution
to risk prediction in hypertensive subjects, but whether
this polymorphism integrated with other risk factors will
enhance the prediction requires additional research. Thus,
the jury must refrain from drawing a conclusion until large,
well-performed studies conﬁrm or refuse our results.
Taken together, we expand previous single studies on
hypertension bysuggesting thatANPgeneT2238Cpolymor-
phism might contribute to the occurrence of hypertension,
especiallyinpopulation-basedstudies.Alsoourobservations
leave open the question regarding the heterogeneous eﬀect
of 2238C allele across diﬀerent ethnic populations. Further
genetic and functional studies are warranted to elucidate the
relationship between T2238C polymorphism and hyperten-
sion, and mechanisms of the ANP gene and hypertension.
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